About Bristol Myers Squibb Co. 
Bristol Myers Squibb Co.
Pharmaceuticals & Biotechnology
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.
Company Coordinates 
Company Details
430 E 29th St Fl 14 , NEW YORK NY : 10016-8367
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 247 Schemes (34.8%)
Foreign Institutions
Held by 593 Foreign Institutions (19.79%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Dr. Giovanni Caforio
Chairman of the Board, Chief Executive Officer
Dr. Vicki Sato
Lead Independent Director
Mr. Peter Arduini
Independent Director
Mr. Robert Bertolini
Independent Director
Mr. Michael Bonney
Independent Director
Mr. Matthew Emmens
Independent Director
Revenue and Profits:
Net Sales:
12,269 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,313 Million
Pharmaceuticals & Biotechnology
USD 127,940 Million (Large Cap)
15.00
NA
80.34%
2.05
51.19%
7.34






